Visiting from the US? Discover Helixafe, our Cancer Driver Interception program →
What we do
About Bioscience
Brochures
Science & innovation News & media Shop NowTalk to an expert
Italianoالعربية中文

Prenatal & neonatal genomics

Advantages

the withdrawal does not involve any abortive or infectious risk

Sure

the withdrawal does not involve any abortive or infectious risk

Simple

a normal venous blood sample is sufficient to proceed

Early

it is performed starting from the 10th week of gestation (up to 24th)

Validated

boasts the largest clinical study ever published (146,958 pregnancies)

Certificate

it is based on a validated and CE certified bioinformatics analysis

Insured

expected insurance coverage up to € 50,000.00

Supported

reimbursement for diagnostic details and / or genetic counseling

Rapid

the test results are obtained and provided in approximately seven working days

Scientific content reviewed by the Bioscience Institute Scientific Board. · Last updated

The information on this page is for general education and does not replace a consultation with a physician.

This page in other languages: Italiano

Prenatal & neonatal genomics

Request information

Tell us your situation and a specialist from this area will get back to you, in your country and your language.

Prenatal screening estimates risk; a positive result is confirmed with a diagnostic test prescribed by your gynaecologist.

Prenatal & neonatal genomics

Non-invasive prenatal screening from week 10, carrier screening for parents and expanded screening for newborns.

Non-invasive prenatal screening from week 10, validated on 112,669 pregnancies, with carrier screening for parents and expanded screening for newborns in the first days of life.

Connect with us on social

Helixafe · US